Active site-directed double mutants of dihydrofolate reductase

Variants of dihydrofolate reductase (DHFR), which confer resistance to antifulates, are used as dominant selectable markers in vitro and in vivo and may be useful in the context of gene therapy. To identify improved mutant human DHFRs with increased catalytic efficiency and decreased binding to methotrexate, we constructed by site-directed mutagenesis four variants with substitutions at both Leu²² and Phe³¹ (i.e., Phe²²-Ser³¹, Tyr²²- Ser³¹, Phe²²-Gly³¹, and Tyr²²-Gly³¹). Antifolate resistance has been observed previously when individual changes are made at these active- site residues. Substrate and antifolate binding properties of these 'double' mutants revealed that each have greatly diminished affinity for antifolates (> 10,000-fold) yet only slightly reduced substrate affinity. Comparison of in vitro measured properties with those of single-residue variants indicates that double mutants are indeed significantly superior. This was verified fur one of the double mutants that provided high-level methotrexate resistance following retrovirus-mediated gene transfer in NIH3T3 cells.